The Ticker: EZchip CEO Defends Valuation Assigned to the Company in Mellanox Merger

Clal Biotech, Access invest $10 million in U.S. cancer-therapy startup; Tel Aviv shares start quarter with a yawn.

comments Print
EZchip CEO defends valuation assigned to the company in Mellanox merger